Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Academic Article uri icon

Overview

abstract

  • We conducted a phase II evaluation of edatrexate in 17 previously untreated patients with advanced adenocarcinoma of the pancreas; 14 patients had at least one month of therapy. The initial dose was 80 mg/m2iv. Treatment was administered weekly for 5 weeks, then every other week. Toxicity was generally mild. The median WBC nadir was 5.4 (range 0.6-7.4) x 10(3)/microliters, and the median platelet nadir was 164.0 (range 62.0-341.0) x 10(3)/microliters. One patient died with sepsis and gastrointestinal bleeding associated with pancytopenia. Five patients had a mild rash. Nausea occurred in 6 patients, including 3 who had vomiting. In addition, 11 patients complained of vague malaise which seemed to begin within 24-48 hours after administration of edatrexate, and lasted for 2 to 3 days, resolving within 6 days of drug administration. Median survival was 85 days. Although 5 patients had stable disease, including one with relief of pain, no major responses were seen, excluding, with 95% confidence, a response rate in excess of 20%.

publication date

  • November 1, 1992

Research

keywords

  • Adenocarcinoma
  • Aminopterin
  • Antineoplastic Agents
  • Pancreatic Neoplasms

Identity

Scopus Document Identifier

  • 0027056402

Digital Object Identifier (DOI)

  • 10.1007/BF00944187

PubMed ID

  • 1487406

Additional Document Info

volume

  • 10

issue

  • 4